273 related articles for article (PubMed ID: 11559309)
1. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
Dewey RB; Hutton JT; LeWitt PA; Factor SA
Arch Neurol; 2001 Sep; 58(9):1385-92. PubMed ID: 11559309
[TBL] [Abstract][Full Text] [Related]
2. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
4. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Grosset KA; Malek N; Morgan F; Grosset DG
J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
[TBL] [Abstract][Full Text] [Related]
5. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
7. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
LeWitt PA; Ondo WG; Van Lunen B; Bottini PB
Clin Neuropharmacol; 2009; 32(2):89-93. PubMed ID: 18978491
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
Nomoto M; Kubo S; Nagai M; Yamada T; Tamaoka A; Tsuboi Y; Hattori N;
Clin Neuropharmacol; 2015; 38(6):241-7. PubMed ID: 26536022
[TBL] [Abstract][Full Text] [Related]
12. Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study.
Grosset KA; Malek N; Morgan F; Grosset DG
Acta Neurol Scand; 2013 Sep; 128(3):166-71. PubMed ID: 23527823
[TBL] [Abstract][Full Text] [Related]
13. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.
Ostergaard L; Werdelin L; Odin P; Lindvall O; Dupont E; Christensen PB; Boisen E; Jensen NB; Ingwersen SH; Schmiegelow M
J Neurol Neurosurg Psychiatry; 1995 Jun; 58(6):681-7. PubMed ID: 7608665
[TBL] [Abstract][Full Text] [Related]
14. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
15. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
Rascol O; Azulay JP; Blin O; Bonnet AM; Brefel-Courbon C; Césaro P; Damier P; Debilly B; Durif F; Galitzky M; Grouin JM; Pennaforte S; Villafane G; Yaici S; Agid Y
Mov Disord; 2010 Feb; 25(3):368-76. PubMed ID: 20063435
[TBL] [Abstract][Full Text] [Related]
16. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
Pfeiffer RF; Gutmann L; Hull KL; Bottini PB; Sherry JH;
Parkinsonism Relat Disord; 2007 Mar; 13(2):93-100. PubMed ID: 17055329
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
18. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
Grosset KA; Malek N; Morgan F; Grosset DG
Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
[TBL] [Abstract][Full Text] [Related]
19. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Factor SA
Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
[TBL] [Abstract][Full Text] [Related]
20. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
van Laar T; Jansen EN; Essink AW; Neef C; Oosterloo S; Roos RA
Clin Neurol Neurosurg; 1993 Sep; 95(3):231-5. PubMed ID: 8242966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
